12 citations
,
December 2010 in “Journal of thoracic oncology” New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
9 citations
,
June 2022 in “Microorganisms” We need safe, affordable drugs to fight coronaviruses effectively.
Pvalb8 is essential for zebrafish hearing and hair cell development, and its mutation causes hearing loss.
8 citations
,
September 2023 in “International Journal of Nanomedicine” A new lab-grown lung model helps study adenoviruses and test antiviral drugs.
30 citations
,
June 1993 in “The Journal of Cell Biology” The oncoprotein causes abnormal hair growth without increasing skin cancer risk.
January 2024 in “Inflammation and regeneration” Th22 cells are essential for Tβ15-induced hair growth in mice.
April 2016 in “Chinese Journal of Dermatology” Wnt10b can help regenerate hair follicles.
7 citations
,
July 2013 in “International Journal of Dermatology” No link found between Coxsackie viruses and pemphigus.
1 citations
,
January 2025 in “OBM Geriatrics” Platelets play a key role in the immune system and their lifespan and aging are important for developing new treatments.
2 citations
,
December 2011 in “Annales de Dermatologie et de Vénéréologie” 2011 dermatological research found new skin aging markers, hair loss causes, skin defense mechanisms, and potential for new treatments.
21 citations
,
June 2023 in “Journal of Nanobiotechnology” Engineered extracellular vesicles could improve CRISPR/Cas delivery, making gene editing safer and more effective.
5 citations
,
December 2022 in “Molecular Biology” Effective delivery of gene editors is crucial for safe and successful gene editing in healthcare and agriculture.
23 citations
,
January 2022 in “Biomaterials Science” Non-viral vectors show promise for safe and effective CRISPR/Cas9 gene editing in treating diseases.
March 2025 in “Nature Communications” NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
April 2021 in “Journal of Investigative Dermatology” The new skin-targeted COVID-19 vaccine creates strong immune responses and could improve vaccination methods.
30 citations
,
January 2014 in “Journal of Controlled Release” This method is effective for needle-free HIV-1 vaccination by activating immune responses in the skin.
December 2013 in “Pump Industry Analyst” The method effectively delivers vaccines through the skin without needles.
December 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” The new vaccine platform led to a stronger immune response and better protection against the flu than the traditional vaccine.
6 citations
,
February 2009 in “Journal of Investigative Dermatology” 7 citations
,
March 2011 in “The Journal of Gene Medicine” Lentiviral vector effectiveness in skin is influenced by external factors, not receptor availability.
September 2025 in “Advanced Pharmaceutical Bulletin” Genosomes are promising for safe and effective gene delivery in therapy.
21 citations
,
January 2022 in “Biomaterials Science” RNA delivery is best for in-body use, while RNP delivery is good for outside-body use. Both methods are expected to greatly impact future treatments.
37 citations
,
December 2020 in “Molecules” A new delivery system makes Curcumin more effective and safer against viruses.
January 2011 in “Anhui nongye kexue” The vector successfully directed specific gene expression in hair follicles.
41 citations
,
November 2024 in “Molecular Biomedicine” Engineered extracellular vesicles show promise for targeted therapy but need more research for clinical use.
14 citations
,
January 2024 in “Theranostics” Intranasal delivery of gene therapy shows promise for treating ischemic stroke.
100 citations
,
November 2021 in “Cell Research” Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
46 citations
,
October 2022 in “Biomaterials”
3 citations
,
September 2023 in “Advanced science” A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.
January 2026 in “Pediatrics International” Live vaccines can be safely given to infants with a FOXN1 variant if their immune function improves over time.